<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692975</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/30</org_study_id>
    <nct_id>NCT03692975</nct_id>
  </id_info>
  <brief_title>MRI Hippocampal Microstructure and Episodic Memory in Early Multiple Sclerosis</brief_title>
  <acronym>Micro-MS</acronym>
  <official_title>Hippocampal Microstructure Assessed by a New MRI Sequence and Episodic Memory at the Early Stage of Multiple Sclerosis: Comparison Between Patients After a Clinically Isolated Syndrome (CIS) and Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinically isolated syndrome (CIS) can evolve into multiple sclerosis. In CIS patients,&#xD;
      episodic memory is frequently impaired. Memory disorders could be preceded by microstructural&#xD;
      abnormalities without visible atrophy in hippocampus. A recent MRI imaging of diffusion&#xD;
      called NODDI (Neurite Orientation Dispersion and Density Imaging) can measure specifically&#xD;
      microstructural abnormalities and map the axons in the white matter (WM) and dendrites in the&#xD;
      grey matter (GM). The aim of this study is to evaluate microstructural abnormalities in the&#xD;
      dentate gyrus of the hippocampus in CIS patients compared to controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cognitive deficiencies could occur after a first clinical event of the central nervous system&#xD;
      suggestive of MS called clinically isolated syndrome (CIS). Cognitive impairment concerned&#xD;
      several cognitive domains including episodic memory, attention, working memory and executive&#xD;
      functions. It is recognized the negative impact of cognitive impairment on quality of life&#xD;
      and vocational status in patients living with MS. Slowness of information processing speed is&#xD;
      the main cognitive dysfunction observed in MS seen at the earliest stage of the disease.&#xD;
      Recently an international group of MS experts has explain IPS and episodic memory as the&#xD;
      minimal cognitive assessment in patients with MS. Visuospatial and verbal episodic memory&#xD;
      deficits have been observed in 18 to 28% of patients assessed after a CIS.&#xD;
&#xD;
      Memory disorders could be preceded by microstructural abnormalities without visible atrophy&#xD;
      in hippocampus. A recent MRI imaging of diffusion called NODDI (Neurite Orientation&#xD;
      Dispersion and Density Imaging) can measure specifically microstructural abnormalities and&#xD;
      map the axons in white matter and dendrite in the gray matter. No study has used the NODDI in&#xD;
      CIS patients and very few studies have been conducted in MS.&#xD;
&#xD;
      The hypothesis is that the dentate gyrus is the anatomical substrate of early episodic memory&#xD;
      dysfunction in patients included after a CIS.&#xD;
&#xD;
      The identification of predictive MRI biomarker of memory impairment would be a useful and&#xD;
      clinically relevant prognostic marker at the early stage of MS. This biomarker could&#xD;
      contribute to determine the prognosis of the disease and could help for the monitoring of the&#xD;
      patients in clinical practice and clinical trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Index of orientation-dispersion (IOD)</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>This parameter is measured in the dentate gyrus of hippocampus from NODDI imaging blind to the nature of the patient's group (CIS patients and controls).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Index of Neurite density (ND)</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>This parameter is measured in the dentate gyrus of hippocampus from NODDI imaging blind to the nature of the patient's group (CIS patients and controls).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diffusion parameters : Index of orientation-dispersion</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>This parameter is measured in thalamus and cerebellum from NODDI imaging blind to the nature of the patient's group (CIS patients and controls).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion parameters : Neurite density</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>This parameter is measured in thalamus and cerebellum from NODDI imaging blind to the nature of the patient's group (CIS patients and controls).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion parameters : Fractional Anisotropy</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>This parameter is measured in dentate gyrus of hippocampus, thalamus and cerebellum from diffusion imaging blind to the nature of the patient's group (CIS patients and controls).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion parameters : Mean diffusivity</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>This parameter is measured in dentate gyrus of hippocampus, thalamus and cerebellum from diffusion imaging blind to the nature of the patient's group (CIS patients and controls).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrophy parameters</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>Normalized total brain volume and normalized total WM and total GM volumes and in hippocampus, thalamus and cerebellum from 3D-T1, 3D-DIR, 3D-WMn-MPRAGE in CIS patients and controls in double-blind.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion volume</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>Normalized volume of lesions double-blind measured by a semi-automatic method based on 3 D Fast Fluid-attenuated inversion-recuperation (3D-FLAIR) and 3 D Double Inversion Recovery (3D-DIR) in whole brain and in the hippocampus, thalamus and cerebellum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory activity</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>The inflammatory activity will be the number of T1-gadolinium enhancing lesions in whole brain and in the hippocampus, thalamus and cerebellum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connectivity</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>The seed-based connectivity is measured between hippocampus and others cerebral regions (Thalamus, cerebellumâ€¦) from Diffusion Tensor Imaging (DTI) and resting state functional imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal episodic memory test</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>California Verbal Learning Test-Second version (CVLT-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual episodic memory score</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>Brief Visual Memory Test-Revised (BVMT-R) and Memonic Similarity Task (MST) : visuospatial memory tests (2 scores pour BVMT-R, 3 scores pour MST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Information processing speed and attention score</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>Computerized Speed Cognitive Test (CSCT) and TAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working memory score</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>Paced-Auditory-Serial-Addition-Test (PASAT) and span</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>CIS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially suggestive of multiple sclerosis (MS) whatever the mode of presentation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 Healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical assessment</intervention_name>
    <description>Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.</description>
    <arm_group_label>CIS patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuropsychological evaluation</intervention_name>
    <description>cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.</description>
    <arm_group_label>CIS patients</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychological evaluation</intervention_name>
    <description>included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve</description>
    <arm_group_label>CIS patients</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI Evaluation</intervention_name>
    <description>Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI</description>
    <arm_group_label>CIS patients</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - PATIENTS:&#xD;
&#xD;
               -  Men and Women,&#xD;
&#xD;
               -  Age 18-60 years,&#xD;
&#xD;
               -  Native French language,&#xD;
&#xD;
               -  Clinically isolated neurological syndrome (CIS) compatible with a demyelinating&#xD;
                  inflammatory episode within the central nervous system, potentially beginning&#xD;
                  multiple sclerosis (MS) whatever the mode of presentation,&#xD;
&#xD;
               -  Between 60 and 180 days from the onset,&#xD;
&#xD;
               -  At least two clinically silent lesions on their T2-weighted brain or spinal MRI&#xD;
                  scan with a size of least 3 mm, at least one of which being cerebral, ovoid, or&#xD;
                  periventricular,&#xD;
&#xD;
               -  Willing to participate and to sign informed consent.&#xD;
&#xD;
          -  - HEALTHY CONTROLS&#xD;
&#xD;
               -  Men and Women,&#xD;
&#xD;
               -  Age 18-60years,&#xD;
&#xD;
               -  Native French language,&#xD;
&#xD;
               -  Willing to participate and to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - PATIENTS:&#xD;
&#xD;
               -  Prior documented neurological episode suggestive of MS,&#xD;
&#xD;
               -  History of neurological disease and/or other neurological diseases,&#xD;
&#xD;
               -  Psychiatric diseases,&#xD;
&#xD;
               -  Known chronic systemic diseases as judged by the investigator,&#xD;
&#xD;
               -  Alcohol or other addiction to toxic,&#xD;
&#xD;
               -  Disabling visual or motor problems preventing participation to neuropsychological&#xD;
                  assessments,&#xD;
&#xD;
               -  Acquisition disorders : Dyslexia, Dysphasia, Dyscalculia and dyspraxia,&#xD;
&#xD;
               -  Dosage change, stop or start of hypnotic or anxiolytic or antidepressive&#xD;
                  treatment less than 30 days,&#xD;
&#xD;
               -  Contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves,&#xD;
                  ear implants, metal fragments or foreign objects in the eyes, skin or body,&#xD;
                  claustrophobia),&#xD;
&#xD;
               -  Steroid treatment less than one month (be taken orally or by infusion) at the&#xD;
                  dosage of 500mg daily,&#xD;
&#xD;
               -  Illiteracy, is unable to count or to read,&#xD;
&#xD;
               -  Pregnant or breastfeeding women,&#xD;
&#xD;
               -  Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their&#xD;
                  liberty by a judicial or administrative decision, minors, persons of legal age&#xD;
                  who are the object of a legal protection measure or unable to express their&#xD;
                  consent).&#xD;
&#xD;
          -  - HEALTHY CONTROLS&#xD;
&#xD;
               -  History of neurological disease and/or neurological diseases,&#xD;
&#xD;
               -  Psychiatric diseases,&#xD;
&#xD;
               -  Known chronic systemic diseases as judged by the investigator,&#xD;
&#xD;
               -  Alcohol or other addiction to toxic,&#xD;
&#xD;
               -  Acquisition disorders: Dyslexia, Dysphasia, Dyscalculia and dyspraxia,&#xD;
&#xD;
               -  Known cognitive impairment or Prior neuropsychological testing with the same&#xD;
                  tests less than one year,&#xD;
&#xD;
               -  Hypnotic or anxiolytic or antidepressive treatment,&#xD;
&#xD;
               -  Steroid treatment less than one month (be taken orally or by infusion) at the&#xD;
                  dosage of 500mg daily,&#xD;
&#xD;
               -  Contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves,&#xD;
                  ear implants, metal fragments or foreign objects in the eyes, skin or body,&#xD;
                  claustrophobia) or refusing MRI,&#xD;
&#xD;
               -  Illiteracy, unable to count or to read,&#xD;
&#xD;
               -  Pregnant or breastfeeding women,&#xD;
&#xD;
               -  Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their&#xD;
                  liberty by a judicial or administrative decision, minors, persons of legal age&#xD;
                  who are the object of a legal protection measure or unable to express their&#xD;
                  consent).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AurÃ©lie RUET, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric FRISON, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AurÃ©lie RUET, MD, PhD</last_name>
    <phone>(0)5 56 79 55 21</phone>
    <phone_ext>+33</phone_ext>
    <email>aurelie.ruet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathilde DELOIRE, PhD</last_name>
    <phone>(0)5 57 82 12 75</phone>
    <phone_ext>+33</phone_ext>
    <email>mathilde.deloire@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - service de neurologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AurÃ©lie RUET, MD, PhD</last_name>
      <phone>(0)5 56 79 55 21</phone>
      <phone_ext>+33</phone_ext>
      <email>aurelie.ruet@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mathilde DELOIRE, PhD</last_name>
      <phone>(0)5 57 82 12 75</phone>
      <phone_ext>+33</phone_ext>
      <email>mathilde.deloire@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>AurÃ©lie RUET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno BROCHET, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe OUALLET, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CÃ©cile DULAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amandine MOROSO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinically Isolated Syndrome</keyword>
  <keyword>NODDI</keyword>
  <keyword>Hippocampus</keyword>
  <keyword>episodic memory function</keyword>
  <keyword>dentate gyrus</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

